Serum Institute of India

New Delhi: The Pune-based Serum Institute of India (SII) will start manufacturing the anti-COVID vaccine Sputnik V from September, Russian authorities said on Tuesday. The RDIF (Russian Direct Investment Fund) said they “intend to produce…

Pune: Serum Institute of India (SII) confirmed that it suffered losses to the tune of Rs 1,000 crore in Thursday’s fire, though the supplies or production of the COVID-19 vaccine are unaffected. “The fire incident will not affect…

Pune: The fire at Serum Institute of India (SII) that killed five workers on Thursday won’t result in any loss of Covishield coronavirus vaccine due to “multiple production buildings”, but will have an impact on BCG and rotavirus vaccines.…

Pune: The CEO of Serum Institute of India (SII), Adar Poonawalla, on Tuesday said his firm has decided to sell the first 100 million doses of Covishield vaccine at a special price to the government. Poonawalla said the SII will be selling…

New Delhi: A day ahead of the scheduled dry run for vaccination in all the states, a government-appointed panel of experts on Friday cleared the Oxford COVID-19 vaccine manufactured by the Serum Institute of India (SII). The panel will now…

New Delhi: India will require funding of Rs 80,000 crore for distribution of the COVID vaccine for the next one year, said Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, ZeeNews…

New Delhi: Serum Institute of India (SII) and Bharat Biotech have not been granted emergency use authorisation of their coronavirus vaccine because of inadequate safety and efficacy data. According to sources, a panel of experts have asked…

New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country. The Pune-based SII is conducting the India trials of Covishield vaccine developed by AstraZeneca and…

Pune: The Serum Institute of India (SII) has said it will file a Rs 100-crore defamation suit against a Covishield vaccine trial participant for “malicious and misconceived” that he had suffered a “virtual neurological breakdown” after…

Chennai: In a setback to the development of COVID-19 vaccines in India, a 40-year-old man has sent a legal notice to Serum Institute of India (SII) and others seeking Rs 5 crore in compensation, and also sought a halt to the ongoing…